Literature DB >> 12074402

Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.

R Jüri Palisaar1, Markus Graefen, Pierre I Karakiewicz, Peter G Hammerer, Edith Huland, Alexander Haese, Salvator Fernandez, Andreas Erbersdobler, Rolf-Peter Henke, Hartwig Huland.   

Abstract

OBJECTIVE: To identify risk factors for biochemical failure after radical prostatectomy (RP) in men with pathologically organ-confined (OC) prostate cancer (PCa).
METHODS: Clinical and pathological characteristics of 331 consecutive men with pT2N0 PCa treated solely with RP were used in Cox proportional hazard models to identify independent predictors of prostate specific antigen (PSA) failure (PSA > or = 0.1 ng/ml). All pathologic specimens were step sectioned at 3 mm.
RESULTS: Twelve patients (3.6%) failed at a median follow-up of 26 months (range 0.2-99.6 months) and 120 men remained at risk 3 years after RP. In univariate Cox models PSA (P < 0.001), percentage of high-grade cancer (P < 0.001) total and high-grade cancer volume (P = 0.001 and P < 0.0001, respectively) and RP Gleason sum (P = 0.003) represented significant predictors of PSA failure. Clinical stage (P = 0.4), surgical margin status (P = 0.3), age (P = 0.2), and pathologic evidence of unilateral versus bilateral PCa (P = 0.6) failed to reveal significance. In receiver operator curve (ROC) analyses, high-grade cancer volume achieved highest outcome predictive accuracy (area under the curve (AUC 0.93)), which was not exceeded by Cox regression-based nomogram combining serum PSA, RP Gleason sum, margin status and pathologic evidence of unilateral versus bilateral PCa (AUC 091). Predictive accuracy of this multivariate nomogram was not enhanced by adding total cancer volume (AUC 0.93), high-grade cancer volume (AUC 0.90), or percentage of high-grade cancer (AUC 0.90).
CONCLUSIONS: In pT2N0 PCa high-grade cancer volume appears to represent the most important pathologic factor for prediction of outcome following RP. However, similar predictive accuracy may be achieved by combining routinely available tumor characteristics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074402     DOI: 10.1016/s0302-2838(01)00025-2

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

1.  Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911).

Authors:  Theodorus H van der Kwast; Laurence Collette; Hein Van Poppel; Paul Van Cangh; Kris Vekemans; Luigi DaPozzo; Jean-François Bosset; Karl H Kurth; Fritz H Schröder; Michel Bolla
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

2.  Advances in the Medical Treatment of Prostate Cancer, Bladder Cancer, Renal Cell Cancer, and Benign Prostatic Hyperplasia: Highlights from the XVIIth Congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002.

Authors:  Christian Seitz; Mesut Remzi; Bob Djavan; Claus G Roehrborn
Journal:  Rev Urol       Date:  2003

3.  Percent tumor volume predicts biochemical recurrence after radical prostatectomy: multi-institutional data analysis.

Authors:  Cheryn Song; Seongil Seo; Hanjong Ahn; Seok-Soo Byun; Jin Seon Cho; Young Deuk Choi; Eunsik Lee; Hyun Moo Lee; Sang Eun Lee; Han Yong Choi
Journal:  Int J Clin Oncol       Date:  2011-08-05       Impact factor: 3.402

4.  Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy.

Authors:  Georg Müller; Malte Rieken; Gernot Bonkat; Joel Roman Gsponer; Tatjana Vlajnic; Christian Wetterauer; Thomas C Gasser; Stephen F Wyler; Alexander Bachmann; Lukas Bubendorf
Journal:  Virchows Arch       Date:  2014-08-17       Impact factor: 4.064

5.  The association between tumour density and prostate cancer recurrence following radical prostatectomy.

Authors:  Luke T Lavallée; Rodney H Breau; Mark A Preston; Gayanna Raju; Christopher Morash; Steve Doucette; Ronald G Gerridzen; James Eastham; Ilias Cagiannos
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

6.  The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.

Authors:  Christian Arsov; Nikolaus Becker; Robert Rabenalt; Andreas Hiester; Michael Quentin; Frederic Dietzel; Gerald Antoch; Helmut E Gabbert; Peter Albers; Lars Schimmöller
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-27       Impact factor: 4.553

7.  Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307 patients with prostate cancer.

Authors:  Beatrice Detti; Silvia Scoccianti; Sara Cassani; Samantha Cipressi; Donata Villari; Alberto Lapini; Calogero Saieva; Tommaso Cai; Maurizio Pertici; Irene Giacomelli; Lorenzo Livi; Marco Ceroti; Giulio Nicita; Marco Carini; Giampaolo Biti
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-18       Impact factor: 4.553

8.  Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins.

Authors:  Christian P Meyer; Jens Hansen; Katharina Boehm; Derya Tilki; Firas Abdollah; Quoc-Dien Trinh; Margit Fisch; Guido Sauter; Markus Graefen; Hartwig Huland; Felix K H Chun; Sascha A Ahyai
Journal:  World J Urol       Date:  2016-06-03       Impact factor: 4.226

9.  Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.

Authors:  Nigel P Murray; Eduardo Reyes; Nelson Orellana; Cynthia Fuentealba; Leonardo Bádinez; Ruben Olivares; José Porcell; Ricardo Dueñas
Journal:  ScientificWorldJournal       Date:  2013-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.